

2026-2027 Respiratory Syncytial Virus (RSV) Prevention Programs

FOR YORK REGION HEALTHCARE PROFESSIONALS as of September 29, 2026

The 2026-2027 RSV Prevention Programs target the highest risk populations and settings. RSV season is generally between early November until the end of March, peaking in December. Administering RSV vaccines and monoclonal antibodies in the fall, as well as flu and COVID-19 vaccines, may:

- Provide protection to high-risk infants and older adults
- Protect individual health and the health of families and communities
- Protect and mitigate impacts on our health care system

The RSV vaccines or the RSV monoclonal antibody can be co-administered with both seasonal and non-seasonal vaccines, including routine childhood immunizations. Co-administration is encouraged to help mitigate the impacts of the respiratory illness season.

Infant and High-Risk Children RSV Prevention Program

Administration of Beyfortus™ and Abrysvo® for the Infant and High-Risk Children RSV Prevention Program can begin on the program launch date, **October 1, 2026**.

Ontario's publicly funded Infant and High-Risk Children RSV Prevention Program eligibility for the 2026-2027 RSV season will be as follows:

- All infants born after April 1, 2026, **and** less than eight months of age in their first RSV season and high-risk children up to 24 months of age in their second RSV season **who meet eligibility criteria** will have access to the Beyfortus™ monoclonal antibody
- Pregnant individuals from 28 to 36 weeks gestational age who will deliver near the start of or during the 2026-2027 season will have the option to receive the RSV vaccine, Abrysvo®, which can help provide protection to infants from birth to six months of age

Note: Administration of both Abrysvo® to the pregnant individual and Beyfortus™ to the infant is **not** recommended except under specific circumstances.

For additional information on [RSV prevention for infants and high-risk children](#), refer to the attached Infant and High-Risk Children RSV Prevention Program Fact Sheet for Health Care Providers.



Older Adult RSV Vaccine Program

There is no seasonal launch date for the Older Adult RSV Vaccine Program. Administration of Arexvy® or Abrysvo® for older adults can occur **year-round** and is not limited to RSV season.

Ontario's publicly funded Older Adult RSV Vaccine Program eligibility is as follows:

- All individuals 75 years of age and older
- Individuals 60 to 74 years of age **who are also**:
 - Residents of long-term care homes, Elder Care Lodges, or retirement homes including similar settings (e.g., co-located facilities)
 - Patients in hospital receiving alternate level of care (ALC) including similar settings (e.g. complex continuing care, hospital transitional programs)
 - Patients with glomerulonephritis (GN) who are moderately to severely immunocompromised
 - Patients receiving hemodialysis or peritoneal dialysis
 - Recipients of solid organ transplants
 - Recipients of hematopoietic stem cell transplants within the past two years or with ongoing immunosuppression
 - Individuals on home oxygen or requiring chronic oxygen therapy, regardless of residence
 - Individuals experiencing homelessness
 - Individuals who identify as First Nations, Inuit, or Métis

Eligible older adults 60 years of age and older are recommended to receive a single dose of either Arexvy® or Abrysvo® to help prevent RSV disease. If an individual has previously received a dose of RSV vaccine, they **do not** need to receive another dose this season, as booster doses are not currently recommended.

For additional information on [RSV prevention for older adults](#), refer to the attached Older Adult RSV Vaccine Program Fact Sheet for Health Care Providers.

Ordering RSV Products

To order RSV products for the Infant and High-Risk Children RSV Prevention Program, complete the attached 2026-2027 Infant and High-Risk Children RSV Prevention Program Product Order Form.

To order RSV vaccines for the Older Adult RSV Vaccine Program, complete the [Publicly Funded Vaccines Order Form](#).

A vaccine refrigeration unit temperature log with a minimum of the most current five (5) business days of temperature recordings must be submitted with each vaccine order form. Submit your order form and temperature log by email to vaccineinventory@york.ca or by fax to 905-830-0578.

Resources

- York Region Public Health's Vaccination Information for Healthcare Professionals [webpage](#)
 - Ministry of Health's vaccine program websites:
 - [2026-2027 Respiratory Syncytial Virus \(RSV\) Prevention Programs](#)
-

Attachments

- Chief Medical Officer of Health's Letter to Health Care Providers
- Health Care Provider Fact Sheet: Infant and High-Risk Children Respiratory Syncytial Virus (RSV) Prevention Program
- Health Care Provider Fact Sheet: Older Adult Respiratory Syncytial Virus (RSV) Vaccine Program
- Patient Fact Sheet: Infant and High-Risk Children Respiratory Syncytial Virus (RSV) Prevention Program

Contact Us

For more information, visit our website at York.ca/VaccineInventory, or contact York Region's Vaccine Inventory Program by phone at 1-877-464-9675 ext. 74033, or by e-mail at vaccineinventory@york.ca

Subscribe to York Region Public Health Matters

Public Health Matters is York Region Public Health's e-update to health care professionals. It includes important updates, opportunities to engage with us and resources you can use in your practice. It highlights programs offered by Public Health that are important to you and for your patients. While we know your inboxes are always full, Public Health Matters will be an invaluable way of staying connected to YRPH now and in the future.

Please [subscribe](#) today!
